Skip to search boxSkip to navigationSkip to main content

Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer

  • J. Al Shemaili
    ,
  • E. Mensah-Brown
    ,
  • K. Parekh
    ,
  • S. A. Thomas
    ,
  • S. Attoub
    ,
  • B. Hellman
*Corresponding author for this work
  • United Arab Emirates University
    ,
  • Uppsala University
    ,
  • Coastside Bio Resources
Research Output:
Contribution to journal
Article
Research
Peer-review

Abstract

Pancreatic cancer has a very poor prognosis. While gemcitabine is the mainstay of therapy and improves quality of life, it has little impact on survival. More effective treatments are desperately needed for this disease. Frondoside A is a triterpenoid glycoside isolated from the Atlantic sea cucumber, Cucumaria frondosa. Frondoside A potently inhibits pancreatic cancer cell growth and induces apoptosis in vitro and in vivo. The aim of the present study was to investigate whether frondoside A could enhance the anti-cancer effects of gemcitabine. Effects of frondoside A and gemcitabine alone and in combination on proliferation were investigated in two human pancreatic cancer cell lines, AsPC-1 and S2013. To investigate possible synergistic effects, combinations of low concentrations of the two drugs were used for a 72 h treatment period in vitro. Growth inhibition was significantly greater with the drug combinations than their additive effects. Combinations of frondoside A and gemcitabine were tested in vivo using the athymic mouse model. Xenografts of AsPC-1 and S2013 cells were allowed to form tumours prior to treatment with the drugs alone or in combination for 30 days. Tumours grew rapidly in placebo-treated animals. Tumour growth was significantly reduced in all treatment groups. At the lowest dose tested, gemcitabine (4 mg/kg/dose), combined with frondoside A (100 μg/kg/day) was significantly more effective than with either drug alone. To conclude: The present data suggest that combinations of frondoside A and gemcitabine may provide clinical benefit for patients with pancreatic cancer.

Research Output Information

Output type

Research Output:
Contribution to journal
Article
Research
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 1391-1398 (8 pages)

Journal (Volume, Issue Number)

European Journal of Cancer (Volume 50, Issue 7)

Publication milestones

  • Published - 05/2014

Publication status

Published - 05/2014

ISSN

0959-8049

Publication IDs

  • Scopus: 84897389846
  • PubMed: 24462376

Publication metrics

Metrics

SciVal
FWCI
0.94
Scopus
citations

PlumX, opens in new tab

Citation count
41
Captures
47

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well